UBS analyst Danielle Antalffy raised the firm’s price target on Johnson & Johnson to $280 from $245 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $280 from $265 at HSBC
- District court rules federal limits to vaccines not based on science, NYT says
- 3 Best ETFs to Invest In, According to AI Analyst, 03/16/2026
- J&J announces Phase 1 study of erdafitinib met primary safety endpoint
- Monte Rosa Therapeutics announces clinical supply agreement with Johnson & Johnson